ES2646565T3 - Tratamiento local de neurofibromas - Google Patents

Tratamiento local de neurofibromas Download PDF

Info

Publication number
ES2646565T3
ES2646565T3 ES06734175.0T ES06734175T ES2646565T3 ES 2646565 T3 ES2646565 T3 ES 2646565T3 ES 06734175 T ES06734175 T ES 06734175T ES 2646565 T3 ES2646565 T3 ES 2646565T3
Authority
ES
Spain
Prior art keywords
agent
neurofibroma
neurofibromas
inhibitors
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06734175.0T
Other languages
English (en)
Spanish (es)
Inventor
Ruihong Chen
Allan E. Rubenstein
Xiaodong Shen
Scott Stewart
Jin-Chen Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncosynergy Inc
Original Assignee
Oncosynergy Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncosynergy Inc filed Critical Oncosynergy Inc
Application granted granted Critical
Publication of ES2646565T3 publication Critical patent/ES2646565T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES06734175.0T 2005-02-02 2006-02-02 Tratamiento local de neurofibromas Active ES2646565T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US64985405P 2005-02-02 2005-02-02
US649854P 2005-02-02
US66981305P 2005-04-07 2005-04-07
US669813P 2005-04-07
PCT/US2006/003588 WO2006083979A2 (fr) 2005-02-02 2006-02-02 Traitement local des neurofibromes

Publications (1)

Publication Number Publication Date
ES2646565T3 true ES2646565T3 (es) 2017-12-14

Family

ID=36777885

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06734175.0T Active ES2646565T3 (es) 2005-02-02 2006-02-02 Tratamiento local de neurofibromas

Country Status (9)

Country Link
US (4) US8211875B2 (fr)
EP (1) EP1853223B1 (fr)
JP (3) JP5710855B2 (fr)
CN (1) CN101155577B (fr)
AU (1) AU2006210787C1 (fr)
CA (1) CA2596759C (fr)
ES (1) ES2646565T3 (fr)
MX (1) MX2007009335A (fr)
WO (1) WO2006083979A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2646565T3 (es) 2005-02-02 2017-12-14 Oncosynergy, Inc. Tratamiento local de neurofibromas
US8329683B2 (en) 2006-06-02 2012-12-11 Nexgenix Pharmaceuticals, Llc Treatment of neurofibromatosis with radicicol and its derivatives
WO2008150302A1 (fr) * 2007-06-04 2008-12-11 Nexgenix Pharmaceuticals Traitement de la neurofibromatose avec du radicicol et ses dérivés
JP2008214331A (ja) * 2007-03-07 2008-09-18 Hirohiko Iida ピンポイント注射りょう法
WO2009030270A1 (fr) * 2007-09-03 2009-03-12 Novartis Ag Dérivés dhydroindoles utilisés pour traiter la maladie de parkinson
MX2010008269A (es) 2008-02-01 2011-02-21 Takeda Pharmaceutical Inhibidores de hsp90.
CA2750762C (fr) 2008-02-21 2016-04-12 The Royal Institution For The Advancement Of Learning/Mcgill University Traitement de maladies neurales ou d'etats neuraux
US9592188B2 (en) 2014-05-22 2017-03-14 Yansong Liu Method of treating or reducing the severity of dermatological conditions
JP6541124B2 (ja) * 2015-03-23 2019-07-10 国立大学法人大阪大学 びまん性神経線維腫用の外用薬
JP2018523665A (ja) 2015-08-06 2018-08-23 キメリックス インコーポレイテッド 抗ウイルス剤として有用なピロロピリミジンヌクレオシドおよびその類縁体
CN111093658B (zh) 2017-05-19 2022-10-14 恩福莱克逊治疗有限公司 用于治疗皮肤疾病的稠合杂芳环-苯胺化合物
CN111065393B (zh) 2017-05-19 2023-08-18 恩福莱克逊治疗有限公司 用于治疗皮肤疾病的吡咯并吡啶-苯胺类化合物
EP3681494A4 (fr) * 2017-09-15 2021-08-04 Ampersand Biopharmaceuticals, Inc. Inhibition des métastases spontanées par des inhibiteurs protéiques des cystéine protéases
US11111264B2 (en) 2017-09-21 2021-09-07 Chimerix, Inc. Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide and uses thereof
JP7406264B2 (ja) 2018-11-20 2023-12-27 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのシアノアリール－アニリン化合物
JP7393808B2 (ja) 2018-11-20 2023-12-07 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのナフチリジノン－アニリン化合物
JP2022511127A (ja) 2018-11-20 2022-01-28 エヌフレクション セラピューティクス インコーポレイテッド あざの処置のためのアリールアニリンおよびヘテロアリールアニリン化合物
EP3883553A4 (fr) 2018-11-20 2022-11-02 NFlection Therapeutics, Inc. Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau
WO2022006512A1 (fr) * 2020-07-02 2022-01-06 The Board Of Regents Of The University Of Texas System Méthodes de traitement du mélanome

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119095A1 (en) * 1992-07-10 2002-08-29 Reinhard Gabathuler Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours
JPH08119865A (ja) * 1994-10-26 1996-05-14 Teijin Ltd 神経線維腫症治療剤
JP3908799B2 (ja) * 1994-10-26 2007-04-25 樹一郎 中山 神経線維腫治療剤
CA2226623A1 (fr) 1995-07-13 1997-01-30 University Of Cincinnati Composes utiles dans le traitement des neurofibromatoses
ATE493983T1 (de) * 1996-11-05 2011-01-15 Childrens Medical Center Thalidomide und dexamethason für die behandlung von tumors
GB9809889D0 (en) * 1998-05-11 1998-07-08 Univ Strathclyde Prevention of restenosis
US7291461B2 (en) * 2002-06-21 2007-11-06 Ptc Therapeutics, Inc. Methods for identifying small molecules that modulate premature translation termination and nonsense mRNA decay
GB2398495B (en) * 2003-01-23 2007-08-22 Kent G Lau A drug delivery preparation comprising at least one anti-tumour drug and a topical carrier for the drug
JP4216680B2 (ja) * 2003-09-25 2009-01-28 知子 菊井 腫瘍・ケロイド等治療剤
US20060160837A1 (en) * 2004-12-29 2006-07-20 The Brigham And Women's Hospital, Inc. Rapamycin compounds in the treatment of neurofibromatosis type 1
ES2646565T3 (es) * 2005-02-02 2017-12-14 Oncosynergy, Inc. Tratamiento local de neurofibromas

Also Published As

Publication number Publication date
US20120315298A1 (en) 2012-12-13
WO2006083979A2 (fr) 2006-08-10
US20130345244A1 (en) 2013-12-26
AU2006210787C1 (en) 2013-01-17
JP2013136617A (ja) 2013-07-11
CN101155577B (zh) 2015-04-22
US8211875B2 (en) 2012-07-03
CA2596759C (fr) 2015-01-13
JP5710855B2 (ja) 2015-04-30
CN101155577A (zh) 2008-04-02
EP1853223B1 (fr) 2017-08-16
AU2006210787A1 (en) 2006-08-10
US20090118240A1 (en) 2009-05-07
JP2008528692A (ja) 2008-07-31
AU2006210787B2 (en) 2012-05-24
MX2007009335A (es) 2007-12-07
JP2015120720A (ja) 2015-07-02
US20150182452A1 (en) 2015-07-02
CA2596759A1 (fr) 2006-08-10
EP1853223A2 (fr) 2007-11-14
US8487004B2 (en) 2013-07-16
WO2006083979A3 (fr) 2006-10-19
WO2006083979B1 (fr) 2007-01-11

Similar Documents

Publication Publication Date Title
ES2646565T3 (es) Tratamiento local de neurofibromas
ES2859518T3 (es) Composición y métodos de tratamiento
Edwards Intra-articular drug delivery: the challenge to extend drug residence time within the joint
Prpich et al. Second intention healing after wide local excision of soft tissue sarcomas in the distal aspects of the limbs in dogs: 31 cases (2005–2012)
Mayhew et al. Minimally invasive treatment of idiopathic chylothorax in dogs by thoracoscopic thoracic duct ligation and subphrenic pericardiectomy: 6 cases (2007–2010)
WO2021067697A1 (fr) Procédés et matériaux pour le traitement de la neurotoxicité
Roux et al. Carmustine wafer implantation for high-grade gliomas: evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery
EP4291239A2 (fr) Composés, compositions et méthodes de traitement de maladies et d'états liés à l'âge
ES2700989T3 (es) Métodos y materiales para tratar estenosis de la válvula aórtica calcificada
Eskafian et al. Gastroscopic study of meloxicam, tramadol, and their combined administration on the development of gastric injuries in dogs
US20150111969A1 (en) J-series prostaglandin-ethanolamides as novel therapeutics
WO2008021981A2 (fr) Traitement local de lésions dermiques et épidermiques hyperprolifératives
JP2005506366A5 (fr)
EP3796918A1 (fr) Promotion de la réparation épithéliale par l'administration d'activateurs de la signalisation pi3k/akt
KR20190137904A (ko) 연골형성의 유도 방법
ES2726401T3 (es) Uso de inhibidores de HDAC para el tratamiento de la destrucción ósea
ES2792850T3 (es) Método para tratar la fibrosis pulmonar idiopática
Milstein et al. The influence of zoledronic acid and cyclophosphamide on microcirculation regeneration in healing oral mucosal flaps
Brown et al. TRPV1 agonist cytotoxicity for chronic pain relief: from mechanistic understanding to clinical application
McDermott et al. Intersphincteric resection: indications and outcome
KR20230061527A (ko) 염증성 장 질환을 치료하는 방법
Trebacz et al. Double-Wound O-Ring Retraction for Chylothorax Surgery in Dogs. Animals 2023, 13, 2567
Vargo et al. Capnography prevents hypoxemia during ERCP and EUS: a randomized controlled trial
CN101203222A (zh) 用于治疗湿疹的丙嗪或紧密相关的化合物
CO-THERAPY et al. OC-005 novel pathway-centric analysis reveals variants associated with toxicity and response to thiopurines in patients with inflammatory bowel disease